Non-Small Cell Lung Cancer Therapeutics Market Report Analysis With Industry Share Insights Shared In Detailed Report

Commonly abbreviated as NSCLC, non-small cell lung cancer is considered to be the most difficult to treat as well as detect. NSCLC shows a very high probability of metastasizing into surrounding tissues including bones, making it a medical nightmare. Unfortunately, almost 90% of lung cancers are NSCLC. The usual therapy for NSCLC includes drug courses that range from targeted therapies to long-term and regular regimens. An increasing number of people are becoming aware of NSCLS, prompting a higher rate of physical checkups.

Obtain Report Details @ https://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

The global non-small cell lung cancer market is exhibiting a CAGR of 12.10% between 2015 and 2023. The market was valued at US$4.9 bn in 2014 and is expected to reach US$15.1 bn by the end of 2023. The key players in the global NSCLC market are Sun Pharmaceutical Industries, Ltd., Genentech, Inc., Pfizer, Inc., Eli Lilly and Company, Novartis AG, Celgene Corporation, Bristol-Myers Squibb, Boehringer Ingelheim, and AstraZeneca plc. In 2014, the global NSCLC market was dominated by Genentech, which a Roche company. It held over 36% of the global NSCLC market in 2014 and was followed by Eli Lilly and Company.

Rising Number of Cancer Patients Expands Scope for Global NSCLC Market

The key driver for the global NSCLC market is the growing incidence of lung cancer, along with advancements in technology that are enabling a faster rate of diagnosis. Other drivers include government initiatives that are creating a wider scope for the approval of therapeutics for NSCLC. With the swift approval to research grants by government bodies for most NSCLC-related labs, the global NSCLC market is expected to witness a new generation of drugs being introduced into the market in the near future.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Angiogenesis Inhibitors Led Global NSCLC Market

The top segments of the global NSCLC market in terms of drug classes are kinase inhibitors, microtubule stabilizers, angiogenesis inhibitors, PD-1/PD-L1 inhibitors, and folate antimetabolites. Of these, the global NSCLC market was led by angiogenesis inhibitors, owing to the possibility of targeted therapies with high efficacy and an increasing demand in Europe, the U.S., and Japan. At the same time, Zykaida is expected to exhibit the fastest growth rate in the global NSCLC market, followed closely by Opdivo.

North America Leads Global NSCLC Market

Owing to a large presence of key players, along with a rapid rate of adoption of NSCLC therapies, North America has led the global NSCLC market till 2014. The market is, however, being shaped by Asia Pacific, the region displaying the fastest growth rate from a geographical perspective. Factors that boost the Asia Pacific NSCLC market are a rapidly increasing population density, coupled with the large number of patients diagnosed with lung cancer due to growing consumption of tobacco products. The region is also experiencing a wider state of medical awareness, which is leading to a greater scope of diagnosis of NSCLC.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=504

The drugs in the global NSCLC market are based on extremely advanced complex proteins, which require large durations for synthesis and research and development. The global NSCLC market, despite its hindrances, is still developing at a rapid rate due to the growing need for therapies against the rampant disease.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.